1. Home
  2. NVAX vs CUBI Comparison

NVAX vs CUBI Comparison

Compare NVAX & CUBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVAX
  • CUBI
  • Stock Information
  • Founded
  • NVAX 1987
  • CUBI 1994
  • Country
  • NVAX United States
  • CUBI United States
  • Employees
  • NVAX N/A
  • CUBI N/A
  • Industry
  • NVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • CUBI Major Banks
  • Sector
  • NVAX Health Care
  • CUBI Finance
  • Exchange
  • NVAX Nasdaq
  • CUBI Nasdaq
  • Market Cap
  • NVAX 2.0B
  • CUBI 1.4B
  • IPO Year
  • NVAX 1995
  • CUBI 2012
  • Fundamental
  • Price
  • NVAX $9.76
  • CUBI $46.46
  • Analyst Decision
  • NVAX Buy
  • CUBI Buy
  • Analyst Count
  • NVAX 6
  • CUBI 8
  • Target Price
  • NVAX $17.83
  • CUBI $63.86
  • AVG Volume (30 Days)
  • NVAX 7.2M
  • CUBI 290.2K
  • Earning Date
  • NVAX 11-07-2024
  • CUBI 10-31-2024
  • Dividend Yield
  • NVAX N/A
  • CUBI N/A
  • EPS Growth
  • NVAX N/A
  • CUBI 33.08
  • EPS
  • NVAX N/A
  • CUBI 7.41
  • Revenue
  • NVAX $987,667,000.00
  • CUBI $722,462,000.00
  • Revenue This Year
  • NVAX N/A
  • CUBI N/A
  • Revenue Next Year
  • NVAX N/A
  • CUBI $11.71
  • P/E Ratio
  • NVAX N/A
  • CUBI $6.12
  • Revenue Growth
  • NVAX N/A
  • CUBI 25.87
  • 52 Week Low
  • NVAX $3.53
  • CUBI $38.69
  • 52 Week High
  • NVAX $23.86
  • CUBI $68.49
  • Technical
  • Relative Strength Index (RSI)
  • NVAX 36.20
  • CUBI 48.18
  • Support Level
  • NVAX $9.52
  • CUBI $44.31
  • Resistance Level
  • NVAX $10.63
  • CUBI $47.11
  • Average True Range (ATR)
  • NVAX 0.57
  • CUBI 1.57
  • MACD
  • NVAX -0.12
  • CUBI 0.05
  • Stochastic Oscillator
  • NVAX 9.97
  • CUBI 28.96

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.

About CUBI Customers Bancorp Inc

Customers Bancorp Inc is a bank holding company engaged in banking activities. It provides financial products and services to small and middle-market businesses, not-for-profits, and consumers. The company operates in Lending Activities, Commercial Lending, Consumer Lending, Private Banking, Deposit Products, Other Funding Sources, and Financial Products and Services. The majority of revenue is derived from commercial lending.

Share on Social Networks: